HDAC9 and Miyoshi myopathy: HDAC inhibitors target epigenetic modifications by inhibiting the deacetylation of histones and non-histone proteins, leading to the reactivation of tumor suppressor genes, disruption of MM cell proliferation, and induction of apoptosis [107].